Hyseq Brews New Drug-Discovery Partnership With Kirin | GenomeWeb

NEW YORK, Aug. 16 – Genomic firm Hyseq and the pharmaceutical division of Japanese brewer Kirin have signed a three-year collaboration to discover proteins and antibodies for a variety of diseases, the firms said on Thursday.

Under the terms of the deal, both companies will share the costs of the discovery process as well as revenue from any discoveries made as a result of the efforts. All discoveries will be shared by the companies, they said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: role for Notch signaling in congenital heart disease, sciatica risk variants, and more.

Researchers in China have used the CRISPR/Cas9 genome editing approach to alter the length of hair fibers in cashmere goats.

According to ScienceInsider, the Scripps Research Institute and the California Institute for Biomedical Research are merging.

National Cancer Institute researchers didn't report severe adverse events to Food and Drug Administration in a timely manner, the Wall Street Journal reports.